PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT (RFP NO. N01DA-2-8821) Release Date: December 13, 2001 NOTICE: NOT-DA-02-021 National Institute on Drug Abuse The National Institute on Drug Abuse (NIDA) is soliciting proposals from qualified organizations having the capability to act as a centralized repository for compounds from domestic and international investigators, commercial sources, and pharmaceutical companies. The contract will involve the receipt, purchase, storage and analysis of compounds from various sources, and the shipment of these compounds to domestic and international test sites, as well as maintenance of an extensive inventory and tracking system. The major goal of this project is to provide NIDA with a holding site which has the capability to inventory, analyze and store compounds, prepared under both GMP (Good Manufacturing Practices) and non-GMP conditions, in amounts ranging from milligram quantities to several kilograms. As some of the compounds may be scheduled under the Controlled Substances Act, demonstration of proper DEA registration and adequate security is mandatory. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. It is anticipated that one cost reimbursement, completion type contract will be awarded for a period of five years with options for additional quantities of work each year. RFP No. N01DA-2-8821 will be available electronically on or about November 15, 2001, and may be accessed through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website at the following address: (URL: http://www.nida.nih.gov/RFP/RFPList.html). Please note that the RFP for this acquisition will be streamlined to include only the Work Statement, Deliverables, Reporting Requirements, Special Requirements, Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. However, all information required for the submission of an offer will be contained in or accessible through the electronic RFP package. Response to the RFP will be due on or about January 3, 2002. This advertisement does not commit the Government to award a contract. Point of Contact: David T. Lisle, Contracts Specialist Contracts Management Branch, OPRM National Institute on Drug Abuse, NIH 6001 Executive Boulevard Room 3105, MSC 9543 Bethesda, MD 20892-9543 E-mail Address: DL115q@nih.gov Telephone: (301) 443-6677 Fax: (301) 443-7595
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||